Protherics Plc - Report of Foreign Issuer (6-K)
October 07 2008 - 6:18AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
7 October 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into
English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.
Yes
No
X
If “Yes” is marked, indicate below the
file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
The Registrant is furnishing a copy of its
announcements as reported to the Company Announcements Office of the London Stock
Exchange.
Protherics PLC
Rule 2.10 announcement
Not for release, publication or distribution (in whole or in part) in, into or from
any jurisdiction where to do so would constitute a violation of the relevant laws of
such jurisdiction.
Lon
don, UK; Brentwood, TN, US: 7 October 2008
-
Protherics PLC
(“Protherics” or the “Company”), the international
biopharmaceutical company focused on critical care and cancer, in accordance with Rule
2.10 of the City Code on Takeovers and Mergers (the “Code”), confirms that
as at the close of business on 6 October 2008, the Company has 342,450,241 ordinary
shares of 2 pence each in issue and admitted to trading on the London Stock Exchange
under the UK ISIN Code GB0007029209.
| Ends |
F
or f
urther
i
nformation
please
contact
:
Protherics
|
|
Nick Staples,
Director of Corporate
Affairs
|
+44 (0) 7919 480510
|
Julie Vickers, Company Secretary
|
+44 (0)1928 518010
|
|
|
Jefferies International Limited
(Financial Adviser)
Ian Crosbie, Director
Nomura Code
Securities Limited
(Corporate Broker)
Phil Walker, Director
Financial Dynamics
– press
enquiries
|
+44 (0) 20 7029 8292
+44 (0) 20 7776 1203
|
London:
Ben Atwell,
Lara Mott
|
+44 (0) 20 7831 3113
|
New York:
John Capodanno
|
+1 212 850 5600
|
Or visi
t
www.protherics.com
Dealing
Disclosure Requirements
Under the provisions of Rule 8.3 of the Code, if any person is, or becomes
"interested" (directly or indirectly) in 1% or more of any class of "relevant
securities" of
Protherics
, all "dealings" in
any
r
elevant securities" of
Protherics
(including by
means of an option in respect of, or a derivative references to, any such "relevant
securities") must be publicly disclosed by no later than 3.30pm (London time) on the
London business day following the date of the relevant transaction. This requirement
will continue until the date on which the offer becomes, or is declared, unconditional
as to acceptances, lapses or is otherwise withdrawn or on which the "offer period"
otherwise ends. If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire an "interest" in "relevant
securities" of
Protherics
they will be
deemed to a single person for the purpose of Rule 8.3.
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities"
of
Protherics by
the potential offeror, or by Protherics,
or by any of
their respective "associates", must be disclosed by no later than 12.00 noon (London
time) on the business day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose "relevant securities"
"dealings" should be disclosed, and the number of such securities in issue, can be
found on the Takeover Panel's website at
www.takeoverpanel.org.uk
.
'Interests in
securities' arise, in summary, when a person has long economic exposure, whether
conditional or absolute, to changes in the price of securities. In particular, a person
will be treated as having an 'interest' by virtue of the ownership or control of
securities, or by virtue of any option in respect of, or derivative referenced to,
securities.
Terms in quotation marks are defined in the Code, which can also be found on the
Panel's website. If you are in any doubt as to whether or not you are required to
disclose a 'dealing' under Rule 8, you should consult the Panel.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
PROTHERICS PLC
|
|
|
|
|
|
|
|
Date: 7 October 2008
|
|
By:
|
|
/s/ Rolf Soderstrom
|
|
|
|
|
Rolf Soderstrom
|
|
|
|
|
Finance Director
|
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jul 2023 to Jul 2024